SR One led a $150m Series C round in Veradermics.

SR One, a trans-Atlantic biotech venture capital firm, led a $150m Series C round in Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company, with participation from Viking Global Investors, Marshall Wace, Invus, abrdn, Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, Longitude Capital, Suvretta Capital Management and Surveyor Capital. “We believe VDPHL01 represents the rare convergence of scientific innovation, favorable preliminary clinical data, and potential commercial opportunity. For the first time, we’re seeing an oral therapeutic candidate designed specifically for hair regrowth that has the potential to achieve consistent efficacy without compromising safety. We believe that VDPHL01, if approved, can represent a front-line product for one of the largest aesthetics conditions worldwide. We are very proud to back Veradermics as they advance a program that could meaningfully impact both patient outcomes and the dermatology market at large,” Katarina Pance, SR One Senior Associate.